The Obesity Drugs — GLP-1 Duopoly
One in three American adults is obese. Two companies make the drugs that work.
GLP-1 agonist drugs (Mounjaro/Zepbound, Wegovy/Ozempic) deliver 15-25% body-weight loss — a result that no diet, exercise regimen, or prior drug has ever achieved at scale. Eli Lilly and Novo Nordisk are the entire game . Combined GLP-1 revenue topped $80B in 2025 and is projected to hit $150B+ by 2030. The chokepoint isn't science — it's manufacturing . These drugs are hard to make at scale (long peptide chains, specialized auto-injector pens). Capacity has been the binding constraint for three years. Next wave: oral formulations, dual/triple agonists, applications beyond obesity (Alzheimer's, kidney disease, heart failure, addiction).
Manufacturing capacity is a 5+ year build. Every pharma company would love to enter the market; only Lilly and Novo can supply it for at least the next 3-5 years. Generics aren't coming until the early 2030s.
3 names on the watchlist
Mounjaro + Zepbound + Alzheimer's franchise — the leader of the duopoly
The leader of the GLP-1 wave . Mounjaro (diabetes) + Zepbound (obesity) — both same compound, tirzepatide — currently outselling Novo's Wegovy/Ozempic and growing faster. Pipeline: retatrutide (triple-agonist, even better weight loss), oral orforglipron (pill form coming 2025-26), Kisunla (Alzheimer's), Mirikizumab (Crohn's). Manufacturing build-out is on a scale not seen since the antibiotics era.
Wegovy/Ozempic — the other half of the duopoly
Danish pharma company with Ozempic (diabetes) and Wegovy (obesity) — semaglutide compound. Plus Saxenda (older obesity drug) and a deep diabetes franchise. Lost the lead to Lilly in 2024-25 in both weight-loss efficacy and prescription growth. Pipeline: amycretin (oral GLP-1+amylin combo, Phase 2 data strong), CagriSema (next-gen obesity, Phase 3 disappointment 2024).
VK2735 dual-agonist GLP-1 — small-cap M&A target
Pure-play biotech with VK2735 — a Phase 3 dual-agonist that showed up to 15% weight loss in Phase 2 . Without Lilly/Novo-level manufacturing, the only realistic path to scale is M&A. Every quarter without a deal makes the M&A thesis stretch further, but the asset remains real and clinically derisked. Volatile around any pharma earnings call where M&A could be hinted at.
- Fortune Business Insights, Precedence Research · 2025–2026